Health
Johnson & Johnson’s (JNJ) COVID-19 vaccine would have an edge over others without this glitch – AlphaStreet
Johnson & Johnson (NYSE: JNJ) saw its shares climb 2% on Thursday after the company reported positive results from the early-stage trials of its COVID-19 vaccine a day ago. The stock has gained 9% in the past three months and over 8% in the past one year. The companys vaccine candidate has an advantage over its competitors in terms of dosage and storage but this is being hindered by manufacturing issues.
Trial results
On Wednesday, the results from J&Js interim Phase 1/2a trial were published in…
Continue Reading
-
Noosa News24 hours agoQueensland government to review greenhouse gas emission reduction targets
-
Business21 hours agoshould I buy hedged or unhedged ASX US-focused ETFs?
-
Noosa News22 hours agoBrisbane news live: Broken-down train causes peak-hour delays
-
Noosa News22 hours agoSudden death investigation, Maroochydore – Sunshine Coast